Ignite Creation Date:
2025-12-25 @ 1:25 AM
Ignite Modification Date:
2026-01-04 @ 6:17 PM
Study NCT ID:
NCT04276493
Status:
COMPLETED
Last Update Posted:
2024-12-06
First Post:
2020-02-04
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab
Sponsor:
BeiGene
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-03-26
Start Date Type:
ACTUAL
Primary Completion Date:
2023-12-07
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-10-31
Completion Date Type:
ACTUAL
First Submit Date:
2020-02-04
First Submit QC Date:
None
Study First Post Date:
2020-02-19
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2024-11-29
Disp First Post Date Type:
ACTUAL
Last Update Submit Date:
2024-12-03
Last Update Post Date:
2024-12-06
Last Update Post Date Type:
ACTUAL